Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation

This narrative review consolidates traditional and emerging molecular indicators for early detection of chemotherapy-induced cardiotoxicity, clarifying which biomarkers are guideline-endorsed and which remain investigational for cardio-oncology practice.

anthracyclinesdoxorubicintrastuzumabHER2 inhibitorsVEGF inhibitorsimmune checkpoint inhibitorscardiotoxicitycardiac troponinnatriuretic peptidesGDF-15galectin-3sST2cardio-oncologynarrative reviewbiomarkers Oncology Pharmacy

Background Information

New biomarkers offer promise for early detection of chemotherapy-induced heart damage.

Chemotherapy-induced cardiotoxicity (CIC) can significantly impact the long-term health of cancer survivors by causing heart-related complications. Emerging biomarkers such as inflammatory cytokines, fibrosis-related proteins, and non-coding RNAs can provide earlier detection and risk stratification for CIC than traditional markers. While new biomarkers show promise, their clinical use is limited by population study variability; integration with imaging and standardized protocols is needed for effective surveillance. A multiparametric approach may enhance the precision monitoring of chemotherapy-induced cardiotoxicity.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kong Y, He R, He H, Liao L, Wu C, Chen X, Peng X

Citation: Kong Y, He R, He H, et al. Precision Monitoring Strategies for Chemotherapy-Induced Cardiotoxicity: A Review of Molecular Indicators for Early Detection and Risk Stratification. Reviews in cardiovascular medicine. 2026;27(2):45852. doi:10.31083/RCM45852

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →